Systemic oncological treatments in patients with advanced pancreatic cancer: a scoping review and evidence map
Salazar, Josefina (Institut d'Investigació Biomèdica Sant Pau)
Pérez Bracchiglione, Javier Andrés (Institut d'Investigació Biomèdica Sant Pau)
Acosta-Dighero, Roberto (Universidad de Valparaíso)
Meza, Nicolás (Universidad de Valparaíso)
Meade, Adriana-Gabriela (Institut d'Investigació Biomèdica Sant Pau)
Quintana Ruiz, Maria Jesús (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública)
Requeijo, Carolina (Institut d'Investigació Biomèdica Sant Pau)
Rodríguez-Grijalva, Gerardo (Institut d'Investigació Biomèdica Sant Pau)
Santero, Marilina (Institut d'Investigació Biomèdica Sant Pau)
Selva, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Solà Arnau, Ivan (Institut d'Investigació Biomèdica Sant Pau)
Bonfill, X. (Xavier) (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública)
Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group

Date:	2023
Abstract:	Purpose: To identify, describe, and organise currently available evidence regarding systemic oncological treatments (SOTs) (chemotherapy, targeted/biological therapies, and immunotherapy) compared to best supportive care (BSC) for patients with advanced pancreatic cancer (PC). Methods: We conducted a scoping review and evidence mapping, adhering to PRISMA-ScR checklist. We searched MEDLINE, EMBASE, Cochrane Library, Epistemonikos, PROSPERO, and clinicaltrials. gov for eligible studies. We included systematic reviews (SRs), randomised controlled trials (RCTs), quasi-experimental, and observational studies evaluating SOTs compared to BSC or no treatment in patients with advanced PC. Two independent reviewers performed the screening process and data extraction. We developed evidence maps as an interactive visualization display, including the assessed interventions and outcomes. Results: Of the 50,601 records obtained from our search, we included 43 studies: 2 SRs, 16 RCTs, 4 quasi-experimental studies, 20 observational studies, and 1 protocol for a quasi-experimental study. Forty-two studies reported survival-related outcomes and most favoured SOTs, while fve reported toxicity and most favoured BSC. Other patient-centred outcomes, such as quality of life, were scarcely reported. Conclusions: This study highlights the current evidence gaps in studies assessing treatments for patients with advanced PC, mainly the lack of reports of non-survival-related outcomes, pointing out research areas that need further attention to make better recommendations for these patients.
Grants:	Instituto de Salud Carlos III PI18/00034
Note:	Altres ajuts: acords transformatius de la UAB
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Pancreatic neoplasms ; Antineoplastic agents ; Immunotherapy ; Review literature as topic
Published in:	Supportive care in cancer, Vol. 31 Núm. 2 (January 2023) , ISSN 1433-7339

DOI: 10.1007/s00520-022-07564-8
PMID: 36622453

Article 14 p, 1.3 MB

Material complementari 3 p, 22.4 KB

Material complementari 3 p, 123.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles